Wegovy vs Mounjaro: Which Weight Loss Option Is Best?

Both Wegovy and Mounjaro are very useful injectable weight loss alternatives. Mounjaro can have a faster effect because of its dual action, while Wegovy is already established and widely used. Look at side effects, price, and patient reviews to match what is the best treatment for you.

 

Introduction to Wegovy and Mounjaro

Over the recent years, there has been an increase in the demand for advanced weight loss treatments in the UK. With the increase of people in need of medical interventions other than diet and exercise routines, injectable drugs such as Wegovy and Mounjaro have emerged as a key talking point both within the medical and consumer worlds.

Wegovy (semaglutide) and Mounjaro (tirzepatide) fall under a category of drugs that control the level of sugar and appetite in the body. Both were initially used in the management of diabetes, but they have also been shown to be effective in weight loss. However, along with their growing popularity, an urgent question arises of which one suits your goals, budget, and body best.

 

Overview of Weight Loss Solutions

Wegovy (Semaglutide): It is a resemblance of the glucagon-like peptide-1, the hormone that induces appetite, raises satiety, and decreases the emptying ability of the gastric. This system encourages a lower calorie consumption and sustains a calorie consumption

Mounjaro (Tirzepatide): Mounjaro is a GIP and GLP receptor agonist that provides a dual-action mechanism. The added GIP (glucose-dependent insulinotropic polypeptide improves the insulin release, as well as on a synergistic level with GLP-1, which strengthens the impact of metabolic control and reduces appetite.

Mounjaro may potentially have an advantage over similar drugs due to the dual mechanism of Tirzapetide, which is likely to boost weight loss with greater efficacy and speed. But it depends on the needs and preferences of an individual; some patients show the same effect when using GLP-1 only, such as Wegovy.

 

Target Audience

• Wegovy: This can be used for adults with a Body Mass Index (BMI) of ≥30 to ≥27 or experiencing weight-related disorders, including high blood pressure or sleep apnoea
• Mounjaro: Originally an approved medication for type 2 diabetes, but many private clinics are prescribing it off-label to manage obesity. It is appropriate for people who require more intensive metabolic therapy.

NHS and private eligibility

• Wegovy: According to NICE criteria, Wegovy is approved for NHS usage in England for patients with a BMI of 35 or above and at least one weight-related condition.
• Mounjaro: As of 2025, Mounjaro has not yet received NHS approval for weight loss. You can only access it at weight loss clinics, and private prescriptions are accessible.

 

Wegovy vs Mounjaro: Efficacy Comparison

• Wegovy: Average weight loss of up to 15% in 68 weeks was observed in clinical trials referred to as the STEP studies, to which Wegovy is subjected. Even more promising were the outcomes of the UK STEP 1 extension, where the participants who had used the combination of the treatment with a healthy lifestyle improvement demonstrated maintained progress during the study.
• Mounjaro: Mounjaro has demonstrated very good results in its own trials, especially the SURMOUNT 1 and SURMOUNT 2 trials. The people lost as much as 21% of their body weight in a span of 72 weeks, a figure that is, at the moment, the highest average weight loss observed among the drugs that have been approved to treat weight problems.

There have been no direct comparisons of Mounjaro and Wegovy yet. However, initial evidence and independent assessments indicate that Mounjaro can be a little bit more effective in terms of weight loss compared to semaglutide in most patients. This can be attributed to the dual-action mechanism of Mounjaro, targeting both GLP-1 AND GIP receptors, which seem to be more effective in patients with a greater starting BMI or metabolic disorders, such as insulin resistance.

 

Mounjaro vs Wegovy Reviews

Wegovy patients claim that it helps to lose weight gradually and controls the appetite well. Complaints are normally about side effects that are experienced early (nausea, fatigue), and some feel anxiety about the injection during the initial stage. While in Mounjaro, users commonly mention accelerated initial weight loss and a decrease in cravings. However, the adverse effects can be experienced more during the first month.

Though reviews are subjective, they tend to point out real-world results. The clinicians recommend that patients take peer feedback cautiously and after an agreement with the medical provider. It is important to note that patients who opt to change to Mounjaro after taking Wegovy invariably experience improved outcomes, although it takes some time to transition.

 

Common Side Effects

Mounjaro and Wegovy are both GLP-1 receptor agonists, which is why they have the same side effects that commonly affect the gastrointestinal tract, because they slow gastric emptying and impact the gut. The most commonly reported side effects are:

• Nausea
• Vomiting
• Diarrhoea
• Constipation
• Fatigue
• Headache
• Indigestion (dyspepsia)
• Pain or discomfort in the abdomen

Such side effects normally manifest more strongly in the first weeks of medication and may also decrease over time as the body gets used to it. The users of Mounjaro occasionally complain that they have experienced a barely increased level of gastrointestinal upset, which can be explained by the effect of the drug on both GLP-1 and GIP receptors.

 

Serious Side Effects

Both drugs have warnings that are similar to each other:

• Pancreatitis: Even though it is uncommon, it is a serious illness that needs urgent medical attention.
• Problems with the gallbladder: Both can lead to an increased risk of gallstones, particularly where there’s a rapid weight loss.
• Cardiovascular considerations: Although both drugs can reduce the cardiovascular risk of diabetics, the long-term heart safety during weight loss alone has yet to be determined.

 

Pricing Comparison

Wegovy

• Cost per month: £199-£299
• Available in 4-week or 12-week packages with increased dosage

Mounjaro

• Cost per month: £225-£350
• Its dual mechanism and recent market introduction are reflected in its slightly higher cost.

Most privately owned weight loss centers have special deals on monthly plans or lifestyle packages that incorporate nutritional coaching. As of mid-2025, Mounjaro is less accessible, which influences pricing flexibility.

 

 

Insurance Coverage Insights

Wegovy can be available to some patients. Depending on local guidelines, there can be both a waiting list and an eligibility limit, while Mounjaro has no NHS weight-loss prescription as of 2025. It is privately available only.

In the UK, some of the best health insurance policies are starting to cover weight-loss drugs when they are associated with medical necessity, but this is not always the case.

 

Public Perception

Both medications significantly increase engagement on Reddit, especially in communities related to diabetes and weight loss. Common topics of conversation include:

• Management of side effects, including nausea.
• Comparison of monthly cost.
• Updates on progress with pictures.
• Changing prescription drugs.

Users of Wegovy value the consistency and accessibility, while patients on Mounjaro frequently highlight quick fat loss in particular places.

 

Consumer Feedback and Testimonials

Testimonials available from the UK weight loss clinics usually contain:

• I can now control the food cravings-Wegovy users
• The weight loss is quicker than I imagined. However, the initial weeks were rough.

Clinics are making adjustments to dosing and schedules to work with and to provide better support during the adjustment period.

 

Conclusion

The following important considerations must be made while deciding between Wegovy and Mounjaro: cost, side effects, effectiveness, and individual objectives.

Mounjaro might be a good option for people who want to lose as much weight as possible because studies have shown that it can reduce body weight by up to 21 %.

Wegovy may be the best choice for people who prefer a more well-known product with consistent results and greater NHS access because it can reduce weight by up to 15%.

Select Wegovy if you have sensitivity to aggressive therapies, or prefer a well-established medicine, or wish to potentially receive NHS help.

If you require faster results, have a higher beginning BMI, or haven’t responded well to GLP-1 only medications, go for Mounjaro.

 

Why Personalisation Matters

Wegovy vs. Mounjaro is never a decision to make on its own. In luxury clinics in the UK, the treatment programs rely on blood tests, lifestyle, health history, and the goals of the patients.

 

FAQs

• What is the difference between Wegovy and Mounjaro?

Wegovy is a GLP-1 receptor agonist of semaglutide, which curbs appetite and decreases digestion. Mounjaro includes tirzepatide, a bilateral GLP-1 and GIP receptor agonist, which has a more extensive hormonal effect. Mounjaro might cause a higher weight loss, but Wegovy is more developed and covered by HNS as an obesity management drug in the UK.

• Which is more effective for weight loss: Mounjaro or Wegovy?

Mounjaro has exhibited a higher average weight loss during its clinical trials, up to 21 percent compared to Wegovy. Its dual-action nature could provide a better outcome, particularly among the high BMIs, but everyone will react differently, and some patients have an equally great effect with less uncomfortable side effects on Wegovy. Whichever you choose, they can both provide significant weight loss.

• How much does Mounjaro cost in the UK?

Mounjaro is generally available in an exclusive clinic in the UK at £225 to £350 per month. The price can also differ according to the dose, the length of the package, and other services offered. As of 2025, Mounjaro is not available to the NHS to aid weight loss.

• How much does Wegovy cost in the UK?

It would cost approximately £199 to £299 per month at treatment centers in the United Kingdom focusing on weight loss. Wegovy has also been approved to be used in patients eligible for the NHS, which could lessen the out-of-pocket expenses, in other cases, depending on meeting the qualifications and availability.

• What are the side effects of Wegovy and Mounjaro?

The usual side effects involve nausea, diarrhoea, fatigue, and suppression of the appetite. There are serious, although uncommon, dangers, such as pancreatitis and gallbladder problems. The side effects of Mounjaro can be more intense when one is being treated in the early stages. They both need to be dosed gradually and under clinical supervision to ensure tolerability, maintenance, and reduce digestive discomfort.

• Are Wegovy and Mounjaro available on the NHS?

Wegovy can be prescribed on the NHS to those patients whose BMI is 35 or above, and who have weight-related comorbidities. The availability can differ by region. Mounjaro is not yet registered by the NHS as an approved weight loss agent and can only be accessed in a private clinic or by prescription.

• Who is a better candidate for Mounjaro vs Wegovy?

Mounjaro can be appropriate for individuals whose BMIor who did not react to GLP-1-only drugs. Wegovy provides perfect weight loss and is good for tose individuals covered by the NHS. The decision on the best option is based on the health profile, objectives, tolerance to side effects, and the privilege to access private care.

• What do UK patients say about Mounjaro vs Wegovy?

Some of the UK patients reported that Mounjaro provides quicker effects, but in some cases, more severe side effects during the initial stages. Wegovy is usually claimed to be more predictable and more accessible. Individual experience may differ, and numerous patients emphasize the necessity of clinical assistance at the time of beginning the treatment and changing its effect.